查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941760

基因编辑市场规模、份额和趋势分析报告：按产品/服务、技术、最终用途、地区和细分市场预测（2026-2033 年）

Gene Editing Market Size, Share & Trends Analysis Report By Product & Service, By Technology, By End-user, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

基因编辑市场概述

全球基因编辑市场预计到 2025 年价值 58.7 亿美元，预计到 2033 年将达到 185.5 亿美元。

预计从 2026 年到 2033 年，该产业将以 15.71% 的复合年增长率成长。这一增长是由先进基因疗法的日益普及、生物製药研究投资的增加以及对精准医疗需求的不断增长所推动的。

对治疗性基因疗法的需求日益增长

随着医疗保健系统逐渐从治疗症状转向针对病因进行更有针对性的干预，罕见疾病和遗传疾病领域对精准医疗的需求日益增长，这是基因编辑市场的主要驱动力之一。许多罕见疾病是单基因疾病，因此基因编辑技术非常适合直接纠正、惰性或替换缺陷基因。传统的慢性病治疗通常需要终身服药，且疗效有限。然而，基因编辑有望透过一次或极少数的干预措施带来持久的益处。

开发者需要的不仅是基础的编辑工具。他们需要复杂的编辑酶来执行特异性突变的程序，指导RNA设计、递送优化以及可靠的分析检验。这导致对基因编辑试剂、GMP级建构模组以及专业合约研究和生产服务的需求持续成长。这些因素，加上尚未满足的医疗需求、精准医疗策略以及可扩展的平台开发，使得基因编辑技术成为下一代治疗创新发展的关键引擎。

目录

第一章调查方法和范围

第二章执行摘要

3. 基因编辑市场变数、趋势与范围

  • 市场谱系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 产业分析工具
    • SWOT分析
    • PESTEL 分析
    • 波特分析

第四章 基因编辑市场：产品与服务估算及趋势分析

  • 产品和服务市场份额（2025 年和 2033 年）
  • 试剂和耗材
  • 软体和系统
  • 服务

第五章 基因编辑市场：技术预测与趋势分析

  • 按技术分類的市场份额（2025 年和 2033 年）
  • CRISPR-Cas系统
  • 转录活化因子样效应核酸酶（TALENs）
  • 锌指核酸酶（ZFNs）
  • Meganucleases/归巢内切酶
  • 技术趋势与竞争考察

第六章 基因编辑市场：终端使用者估算与趋势分析

  • 按最终用途分類的市场份额（2025 年和 2033 年）
  • 生物技术和製药公司
  • 大学和研究机构
  • 其他最终用户

第七章 基因编辑市场：区域估算与趋势分析

  • 区域市场概览
  • 区域市场占有率分析（2025 年和 2033 年）
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 全球竞争格局

  • 2025年全球市场分析

第九章：北美竞争格局

  • 公司简介
    • Thermo Fisher Scientific Inc.
    • Revvity
    • Danaher
    • Intellia Therapeutics
    • Sangamo Therapeutics
    • Beam Therapeutics
    • Illumina, Inc.
    • Editas Medicine
    • Synthego

第十章：欧洲竞争格局

  • 公司简介
    • Merck KGaA
    • QIAGEN
    • Cellectis SA
    • CRISPR Therapeutics
    • Vivlion GmbH
    • Eurofins Genomics
    • AMSBIO
    • OZ Biosciences

第十一章：亚太地区的竞争格局

  • 公司简介
    • GenScript
    • Takara Bio
    • Macrogen, Inc.
    • BRL MEDICINE
    • Biocytogen
    • BGI Genomics
    • Bioneer
Product Code: GVR-4-68040-845-9

Gene Editing Market Summary

The global gene editing market size was estimated at USD 5.87 billion in 2025 and is projected to reach USD 18.55 billion by 2033, growing at a CAGR of 15.71% from 2026 to 2033. This growth is supported by rising adoption of advanced gene therapies, increasing investments in biopharmaceutical research, and growing demand for precision medicine.

Growing demand for curative genetic therapies

The increasing need for precision medicine in rare and genetic disorders is one of the main factors driving the gene editing market, as health care systems are increasingly inclined to shift from symptomatic management to more targeted, root-cause interventions. Many rare diseases are monogenic, making them appropriate candidates for gene-editing techniques that can directly fix, silence, or alter the defective genes. The customary chronic treatment approaches often entail lifelong prescription of medicines with limited effect. However, gene editing opens the door to either single or very rare interventions with lasting results.

The developers need much more than basic editing tools. They need to perform mutation-specific programs with advanced editing enzymes, guide RNA design, delivery optimization, and robust analytical validation. As a result, there has been a continuous demand for gene-editing reagents, GMP-grade components, and specialized contract research and manufacturing services. The combination of the above factors, namely unmet clinical need, precision-focused healthcare strategies, and scalable platform development, has made gene editing a critical growth engine in the next generation of therapeutic innovations.

Global Gene Editing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global gene editing market report based on product & service, technology, end-user, and region:

  • Product & Service Outlook (Revenue, USD Billion, 2021 - 2033)
  • Reagents and Consumables
  • Software and Systems
  • Services
  • Technology Outlook (Revenue, USD Billion, 2021 - 2033)
  • CRISPR-Cas System
  • Transcription Activator-Like Effector Nucleases (TALENs)
  • Zinc Finger Nucleases (ZFNs)
  • Meganucleases/Homing Endonucleases
  • End-user Outlook (Revenue, USD Billion, 2021 - 2033)
  • Biotechnology and Pharmaceutical Companies
  • University and Research Institutes
  • Other End-users
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product & Service
    • 1.2.2. Technology
    • 1.2.3. End User
  • 1.3. Research Methodology
  • 1.4. Information Procurement
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Gene Editing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing Demand For Curative Genetic Therapies
      • 3.2.1.2. Expansion Of Enabling Ecosystem
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Capital-Intensive Development Pathways
      • 3.2.2.2. Fragmented Regulatory Landscape
    • 3.2.3. Market Opportunity Analysis
      • 3.2.3.1. Monetization Beyond Therapeutic Products
      • 3.2.3.2. Broadening Application Spectrum
    • 3.2.4. Market Challenge Analysis
      • 3.2.4.1. Limitations In Targeted In Vivo Delivery
      • 3.2.4.2. Complex Intellectual Property Environment
    • 3.2.5. Key Partnerships & Collaborations
    • 3.2.6. Patent Analysis
    • 3.2.7. Funding & Investment Landscape
  • 3.3. Industry Analysis Tools
    • 3.3.1. SWOT Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. Porter's Analysis

Chapter 4. Gene Editing Market: Product & Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Product & Service Market Share, 2025 & 2033
  • 4.3. Reagents and Consumables
    • 4.3.1. Reagents and Consumables Market Estimates and Forecasts 2021 to 2033 (USD million)
  • 4.4. Software and Systems
    • 4.4.1. Software and Systems Market Estimates and Forecasts 2021 to 2033 (USD million)
  • 4.5. Services
    • 4.5.1. Services Market Estimates and Forecasts 2021 to 2033 (USD million)

Chapter 5. Gene Editing Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Technology Market Share, 2025 & 2033
  • 5.3. CRISPR-Cas System
    • 5.3.1. CRISPR-Cas System Market Estimates and Forecasts 2021 to 2033 (USD million)
  • 5.4. Transcription Activator-Like Effector Nucleases (TALENs)
    • 5.4.1. Transcription Activator-Like Effector Nucleases (TALENs) Market Estimates and Forecasts 2021 to 2033 (USD million)
  • 5.5. Zinc Finger Nucleases (ZFNs)
    • 5.5.1. Zinc Finger Nucleases (ZFNs) Market Estimates and Forecasts 2021 to 2033 (USD million)
  • 5.6. Meganucleases/Homing Endonucleases
    • 5.6.1. Meganucleases/Homing Endonucleases Market Estimates and Forecasts 2021 to 2033 (USD million)
  • 5.7. Technology Landscape and Competitive Insights

Chapter 6. Gene Editing Market: End User Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. End User Market Share, 2025 & 2033
  • 6.3. Biotechnology and Pharmaceutical Companies
    • 6.3.1. Biotechnology and Pharmaceutical Companies Market Estimates and Forecasts 2021 to 2033 (USD million)
  • 6.4. University and Research Institutes
    • 6.4.1. University and Research Institutes Market Estimates and Forecasts 2021 to 2033 (USD million)
  • 6.5. Other End Users
    • 6.5.1. Other End Users Market Estimates and Forecasts 2021 to 2033 (USD million)

Chapter 7. Gene Editing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2025 & 2033
  • 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework
      • 7.4.1.3. Reimbursement environment
      • 7.4.1.4. Growth drivers
      • 7.4.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Reimbursement environment
      • 7.4.2.4. Growth drivers
      • 7.4.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Reimbursement environment
      • 7.4.3.4. Growth drivers
      • 7.4.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework
      • 7.5.1.3. Reimbursement environment
      • 7.5.1.4. Growth drivers
      • 7.5.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Reimbursement environment
      • 7.5.2.4. Growth drivers
      • 7.5.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Reimbursement environment
      • 7.5.3.4. Growth drivers
      • 7.5.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Reimbursement environment
      • 7.5.4.4. Growth drivers
      • 7.5.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Reimbursement environment
      • 7.5.5.4. Growth drivers
      • 7.5.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Reimbursement environment
      • 7.5.6.4. Growth drivers
      • 7.5.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework
      • 7.5.7.3. Reimbursement environment
      • 7.5.7.4. Growth drivers
      • 7.5.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework
      • 7.5.8.3. Reimbursement environment
      • 7.5.8.4. Growth drivers
      • 7.5.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework
      • 7.6.1.3. Reimbursement environment
      • 7.6.1.4. Growth drivers
      • 7.6.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Reimbursement environment
      • 7.6.2.4. Growth drivers
      • 7.6.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Reimbursement environment
      • 7.6.3.4. Growth drivers
      • 7.6.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Reimbursement environment
      • 7.6.4.4. Growth drivers
      • 7.6.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Reimbursement environment
      • 7.6.5.4. Growth drivers
      • 7.6.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Reimbursement environment
      • 7.6.6.4. Growth drivers
      • 7.6.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework
      • 7.7.1.3. Reimbursement environment
      • 7.7.1.4. Growth drivers
      • 7.7.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Reimbursement environment
      • 7.7.2.4. Growth drivers
      • 7.7.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework
      • 7.8.1.3. Reimbursement environment
      • 7.8.1.4. Growth drivers
      • 7.8.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Reimbursement environment
      • 7.8.2.4. Growth drivers
      • 7.8.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Reimbursement environment
      • 7.8.3.4. Growth drivers
      • 7.8.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework
      • 7.8.4.3. Reimbursement environment
      • 7.8.4.4. Growth drivers
      • 7.8.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Global Competitive Landscape

  • 8.1. Global Market Position Analysis, 2025

Chapter 9. North America Competitive Landscape

  • 9.1. Company Profiles
    • 9.1.1. Thermo Fisher Scientific Inc.
      • 9.1.1.1. Company overview
      • 9.1.1.2. Financial performance
      • 9.1.1.3. Product benchmarking
      • 9.1.1.4. Strategic initiatives
    • 9.1.2. Revvity
      • 9.1.2.1. Company overview
      • 9.1.2.2. Financial performance
      • 9.1.2.3. Product benchmarking
      • 9.1.2.4. Strategic initiatives
    • 9.1.3. Danaher
      • 9.1.3.1. Company overview
      • 9.1.3.2. Financial performance
      • 9.1.3.3. Product benchmarking
      • 9.1.3.4. Strategic initiatives
    • 9.1.4. Intellia Therapeutics
      • 9.1.4.1. Company overview
      • 9.1.4.2. Financial performance
      • 9.1.4.3. Product benchmarking
      • 9.1.4.4. Strategic initiatives
    • 9.1.5. Sangamo Therapeutics
      • 9.1.5.1. Company overview
      • 9.1.5.2. Financial performance
      • 9.1.5.3. Product benchmarking
      • 9.1.5.4. Strategic initiatives
    • 9.1.6. Beam Therapeutics
      • 9.1.6.1. Company overview
      • 9.1.6.2. Financial performance
      • 9.1.6.3. Product benchmarking
      • 9.1.6.4. Strategic initiatives
    • 9.1.7. Illumina, Inc.
      • 9.1.7.1. Company overview
      • 9.1.7.2. Financial performance
      • 9.1.7.3. Product benchmarking
      • 9.1.7.4. Strategic initiatives
    • 9.1.8. Editas Medicine
      • 9.1.8.1. Company overview
      • 9.1.8.2. Financial performance
      • 9.1.8.3. Product benchmarking
      • 9.1.8.4. Strategic initiatives
    • 9.1.9. Synthego
      • 9.1.9.1. Company overview
      • 9.1.9.2. Financial performance
      • 9.1.9.3. Product benchmarking
      • 9.1.9.4. Strategic initiatives

Chapter 10. Europe Competitive Landscape

  • 10.1. Company Profiles
    • 10.1.1. Merck KGaA
      • 10.1.1.1. Company overview
      • 10.1.1.2. Financial performance
      • 10.1.1.3. Product benchmarking
      • 10.1.1.4. Strategic initiatives
    • 10.1.2. QIAGEN
      • 10.1.2.1. Company overview
      • 10.1.2.2. Financial performance
      • 10.1.2.3. Product benchmarking
      • 10.1.2.4. Strategic initiatives
    • 10.1.3. Cellectis S.A.
      • 10.1.3.1. Company overview
      • 10.1.3.2. Financial performance
      • 10.1.3.3. Product benchmarking
      • 10.1.3.4. Strategic initiatives
    • 10.1.4. CRISPR Therapeutics
      • 10.1.4.1. Company overview
      • 10.1.4.2. Financial performance
      • 10.1.4.3. Product benchmarking
      • 10.1.4.4. Strategic initiatives
    • 10.1.5. Vivlion GmbH
      • 10.1.5.1. Company overview
      • 10.1.5.2. Financial performance
      • 10.1.5.3. Product benchmarking
      • 10.1.5.4. Strategic initiatives
    • 10.1.6. Eurofins Genomics
      • 10.1.6.1. Company overview
      • 10.1.6.2. Financial performance
      • 10.1.6.3. Product benchmarking
      • 10.1.6.4. Strategic initiatives
    • 10.1.7. AMSBIO
      • 10.1.7.1. Company overview
      • 10.1.7.2. Financial performance
      • 10.1.7.3. Product benchmarking
      • 10.1.7.4. Strategic initiatives
    • 10.1.8. OZ Biosciences
      • 10.1.8.1. Company overview
      • 10.1.8.2. Financial performance
      • 10.1.8.3. Product benchmarking
      • 10.1.8.4. Strategic initiatives

Chapter 11. Asia Pacific Competitive Landscape

  • 11.1. Company Profiles
    • 11.1.1. GenScript
      • 11.1.1.1. Company overview
      • 11.1.1.2. Financial performance
      • 11.1.1.3. Product benchmarking
      • 11.1.1.4. Strategic initiatives
    • 11.1.2. Takara Bio
      • 11.1.2.1. Company overview
      • 11.1.2.2. Financial performance
      • 11.1.2.3. Product benchmarking
      • 11.1.2.4. Strategic initiatives
    • 11.1.3. Macrogen, Inc.
      • 11.1.3.1. Company overview
      • 11.1.3.2. Financial performance
      • 11.1.3.3. Product benchmarking
      • 11.1.3.4. Strategic initiatives
    • 11.1.4. BRL MEDICINE
      • 11.1.4.1. Company overview
      • 11.1.4.2. Financial performance
      • 11.1.4.3. Product benchmarking
      • 11.1.4.4. Strategic initiatives
    • 11.1.5. Biocytogen
      • 11.1.5.1. Company overview
      • 11.1.5.2. Financial performance
      • 11.1.5.3. Product benchmarking
      • 11.1.5.4. Strategic initiatives
    • 11.1.6. BGI Genomics
      • 11.1.6.1. Company overview
      • 11.1.6.2. Financial performance
      • 11.1.6.3. Product benchmarking
      • 11.1.6.4. Strategic initiatives
    • 11.1.7. Bioneer
      • 11.1.7.1. Company overview
      • 11.1.7.2. Financial performance
      • 11.1.7.3. Product benchmarking
      • 11.1.7.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America gene editing market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 4 North America gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 5 North America gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 6 U.S. gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 7 U.S. gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 8 U.S. gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 9 Mexico gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 10 Mexico gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 11 Mexico gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 12 Canada gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 13 Canada gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 14 Canada gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 15 Europe gene editing market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 17 Europe gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 18 Europe gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 19 Germany gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 20 Germany gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 21 Germany gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 22 UK gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 23 UK gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 24 UK gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 25 France gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 26 France gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 27 France gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 28 Italy gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 29 Italy gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 30 Italy gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 31 Spain gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 32 Spain gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 33 Spain gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 34 Denmark gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 35 Denmark gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 36 Denmark gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 37 Sweden gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 38 Sweden gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 39 Sweden gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 40 Norway gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 41 Norway gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 42 Norway gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific gene editing market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 47 China gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 48 China gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 49 China gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 50 Japan gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 51 Japan gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 52 Japan gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 53 India gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 54 India gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 55 India gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 56 South Korea gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 57 South Korea gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 58 South Korea gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 59 Australia gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 60 Australia gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 61 Australia gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 62 Thailand gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 63 Thailand gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 64 Thailand gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 65 Latin America gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 66 Latin America gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 67 Latin America gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 68 Brazil gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 69 Brazil gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 70 Brazil gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 71 Argentina gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 72 Argentina gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 73 Argentina gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 74 MEA gene editing market, by region, 2021 - 2033 (USD Million)
  • Table 75 MEA gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 76 MEA gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 77 MEA gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 78 South Africa gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 79 South Africa gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 80 South Africa gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 81 Saudi Arabia gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 84 UAE gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 85 UAE gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 86 UAE gene editing market, by end user, 2021 - 2033 (USD Million)
  • Table 87 Kuwait gene editing market, by product & service, 2021 - 2033 (USD Million)
  • Table 88 Kuwait gene editing market, by technology, 2021 - 2033 (USD Million)
  • Table 89 Kuwait gene editing market, by end user, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Gene editing market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Gene editing market value, 2025 (USD billion)
  • Fig. 17 Market trends & outlook
  • Fig. 18 Market dynamics
  • Fig. 19 SWOT analysis
  • Fig. 20 PESTEL analysis
  • Fig. 21 PORTER's analysis
  • Fig. 22 Gene editing market: Product & service outlook key takeaways
  • Fig. 23 Gene editing market: Product & service movement analysis
  • Fig. 24 Reagents and consumables market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Software and systems market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Gene editing market: Technology outlook key takeaways
  • Fig. 28 Gene editing market: Technology movement analysis
  • Fig. 29 CRISPR-Cas system market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Transcription activator-like effector nucleases (TALENs) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Zinc finger nucleases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Meganucleases/homing endonucleases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Gene editing market: End user outlook key takeaways
  • Fig. 34 Gene editing market: End user movement analysis
  • Fig. 35 Biotechnology and pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 University and research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Regional marketplace outlook, 2025 & 2033 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Canada gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Mexico gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 Europe gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Germany gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 UK gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 France gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Italy gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Spain gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Denmark gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Sweden gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Norway gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 64 Asia Pacific gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Japan gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 China gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 India gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 South Korea gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Australia gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Thailand gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Latin America gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Brazil gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Argentina gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 MEA gene editing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 South Africa gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Saudi Arabia gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 UAE gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Kuwait gene editing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 91 Company market position analysis, 2025
  • Fig. 92 Strategic framework - North America
  • Fig. 93 Strategic framework - Europe
  • Fig. 94 Strategic framework - Asia Pacific